Clinical trial
A Multicenter, Double-blind, Randomized, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of Oral BPS-314d-MR added-on to Treprostinil, Inhaled (Tyvaso®) in Subjects With Pulmonary Arterial Hypertension
NCT01908699 is registered in ClinicalTrials.gov with Lung Biotechnology PBC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Double-blind, Randomized, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of Oral BPS-314d-MR added-on to Treprostinil, Inhaled (Tyvaso®) in Subjects With Pulmonary Arterial Hypertension
- Lead sponsor
- Lung Biotechnology PBC
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- May 31, 2013
- Completion date
- February 19, 2019
- Enrollment
- 273 (actual)
- Sites
- 75
Conditions
As the registry lists them; a condition with its own page is linked.